Sign in
Taking peopleNo phase

Sepsis-associated Thrombocytopenia and Platelet Transfusion (STAPT)

Key facts

Who runs it
Nanfang Hospital, Southern Medical University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
1,500 people, planned
Started
15 Nov 2025
Expected to end
31 Mar 2027
Type of study
Observational, 2 groups
Treatments tested
  • SAT patients
Record updated
30 January 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Patients admitted to the ICU between January 2021 and May 2024 and subsequently discharged
  • Age ≥ 18 years
  • Meeting the Sepsis-3.0 diagnostic criteria
  • Platelet count < 100 × 10⁹/L at ICU admission
  • ICU length of stay ≥ 48 hours

Who cannot take part

  • Receipt of chemotherapy, immunosuppressants (e.g., cyclosporine, rituximab), or hematopoietic stem cell/solid organ transplantation within 2 weeks
  • Active bleeding (e.g., major gastrointestinal bleeding, intracranial hemorrhage) or hematologic malignancies (e.g., leukemia, myelodysplastic syndrome, lymphoma)
  • Liver cirrhosis (Child-Pugh class B/C), chronic kidney disease (CKD stage 4-5), or autoimmune diseases (e.g., systemic lupus erythematosus)
  • Pre-existing chronic thrombocytopenia (baseline platelet count <100×10⁹/L for >1 month) or long-term use of antiplatelet/anticoagulant drugs (>2 weeks)
  • Significant baseline coagulation dysfunction at ICU admission:Prothrombin time (PT) >1.5 times the upper limit of normal; Activated partial thromboplastin time (APTT) >1.5 times the upper limit of normal; Fibrinogen level <1.0 g/L
  • Missing >20% of key data (e.g., daily platelet counts, ICU survival status within 28 days)
  • Pregnancy or lactation
  • APACHE II score ≥30 within 24 hours of ICU admission

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Currently, there are no multicenter studies on platelet transfusion for SAT patients, and the benefits and risks of platelet transfusion still require further validation based on large-sample data. In summary, investigating the correlation between platelet transfusion during ICU stay and 28-day mortality in SAT patients, as well as evaluating the impact of platelet transfusion on bleeding, thrombotic events, and inflammation control, is of great significance for optimizing SAT management strategies. This study aims to analyze the effect of platelet transfusion on the prognosis of SAT patients, thereby providing an evidence-based foundation for clinical decision-making.

The 2 groups in the trial

  • Platelet Transfusion Group

    Platelet Transfusion within 14 days after ICU admission

    Treatment: SAT patients

  • No Platelet Transfusion Group

    No Platelet Transfusion within 14 days after ICU admission

    Treatment: SAT patients

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Impact of Platelet Transfusion Therapy on 28-day Mortality in Septic Patients With Thrombocytopenia During ICU Stay: a Multicenter Retrospective Observational Study
Record updated
30 January 2026